A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical giant that is a key player in the weight loss drug market. The firm’s ...

Novo Nordisk NVO announced that it has ended its collaboration with telehealth provider Hims & Hers Health. In addition, the ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...